TrialCancer medicine2023

Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A prospective, open-label, phase II study.

Toshihiko Masui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.